$TMO
Thermo Fisher Scientific Inc. · NYSE · Healthcare
- Market cap
- 249.14B
- Volume
- 2.04M
- P/E
- 35.54
- Day range
- 662.50 – 677.28
- 52w range
- 435.27 – 705.79
- Analyst target
- 750.92
AI Summary
Generating a unique summary for TMO…
AI-generated for information only — not investment advice.
Share this ticker
$TMO -0.40% at 673.82 Ray Dalio and 1 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/TMO
Company summary
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Institutional ownership
Institutions hold 94.00% · insiders 0.13% · 3,618 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 30.92M | $20.83B | 8.36% | 2026-06-30 |
| Vanguard Capital Management LLC | 24.28M | $16.36B | 6.57% | 2026-06-30 |
| State Street Corporation | 16.83M | $11.34B | 4.55% | 2026-06-30 |
| FMR, LLC | 14.08M | $9.49B | 3.81% | 2026-06-30 |
| Morgan Stanley | 10.76M | $7.25B | 2.91% | 2026-06-30 |
| JPMORGAN CHASE & CO | 8.50M | $5.73B | 2.30% | 2026-06-30 |
| Geode Capital Management, LLC | 8.38M | $5.65B | 2.27% | 2026-06-30 |
| Franklin Resources, Inc. | 7.27M | $4.90B | 1.97% | 2026-06-30 |
| Vanguard Portfolio Management LLC | 6.23M | $4.20B | 1.68% | 2026-06-30 |
| Capital World Investors | 6.20M | $4.17B | 1.68% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| PETTITI GIANLUCA | President | Sale at price 614.38 per share. | 4.1K | 2026-08-31 |
| PETTITI GIANLUCA | President | Conversion of Exercise of derivative security at price 309.63 per share. | 3.7K | 2026-08-31 |
| CASPER MARC N | Chief Executive Officer | Sale at price 625.41 - 628.74 per share. | 275.00 | 2026-08-24 |
| CASPER MARC N | Chief Executive Officer | Conversion of Exercise of derivative security at price 309.63 per share. | 275.00 | 2026-08-24 |
| CASPER MARC N | Chief Executive Officer | Sale at price 625.45 - 633.99 per share. | 20.0K | 2026-08-21 |
| CASPER MARC N | Chief Executive Officer | Conversion of Exercise of derivative security at price 309.63 per share. | 20.0K | 2026-08-21 |
| BRITT LISA P | Officer | Sale at price 613.12 per share. | 11.4K | 2026-08-19 |
| BRITT LISA P | Officer | Conversion of Exercise of derivative security at price 418.32 per share. | 11.4K | 2026-08-19 |
| SHAFER MICHAEL D | Officer | Sale at price 600.00 per share. | 25.5K | 2026-08-11 |
| SHAFER MICHAEL D | Officer | Conversion of Exercise of derivative security at price 309.63 - 418.32 per share. | 25.5K | 2026-08-11 |
| HOLMES JOSEPH R. | Officer | Sale at price 584.81 per share. | 420.00 | 2026-08-07 |
| CASPER MARC N | Chief Executive Officer | Sale at price 577.37 - 593.32 per share. | 4.9K | 2026-08-07 |
Analyst ratings
Consensus score 1.44 (1 = strong buy, 5 = sell) · mean target 750.92
- CitigroupBuymain2026-10-23
- BarclaysOverweightmain2026-10-22
- RBC CapitalSector Performmain2026-10-22
- TD CowenBuymain2026-10-22
- StifelBuymain2026-10-22
- BairdOutperformmain2026-10-22
- Morgan StanleyOverweightmain2026-10-13
- TD CowenBuymain2026-10-13
- BarclaysOverweightmain2026-10-07
- CLSAOutperforminit2026-09-03
Earnings
Next report: 2026-10-21
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 4Q2025 | 6.57 | 6.45 | 0.12 |
| 1Q2026 | 5.44 | 5.24 | 0.20 |
| 2Q2026 | 6.03 | 5.71 | 0.32 |
| 3Q2026 | 6.68 | 6.40 | 0.28 |
SEC filings
- 8-KCorporate Changes & Voting Matters2026-10-21Open
- 10-QPeriodic Financial Reports2026-07-31Open
- 8-KCorporate Changes & Voting Matters2026-07-23Open
- 11-KAnnual report of employee stock purchase2026-06-23Open
- SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-28Open
- 8-KCorporate Changes & Voting Matters2026-05-26Open
- DEFA14AProxy Statements2026-05-11Open
- 10-QPeriodic Financial Reports2026-05-01Open
- 8-KCorporate Changes & Voting Matters2026-04-23Open
- ARSAnnual Report to Shareholders2026-04-07Open
Latest TMO news
- Should Illumina Stock Holders Look At Thermo Fisher Instead?
For questions about this article or underlying research, email help@trefis.com.
Fri, 23 Oct 2026 17:36:52 +0000
- Thermo Fisher Scientific (TMO) Benefits on Broad-Based Recovery Across Life-Science Markets
Broyhill Asset Management, a Charlotte-based firm, issued its third-quarter 2026 investor letter. The letter can be downloaded here. The Broyhill Equity Composite decreased by 0.3% in Q3, underperforming the MSCI All Country World Index, which gained 1.7%. For the first nine months of the year, the Composite returned 1.9%, compared to 13.4% for the Index. The […]
Fri, 23 Oct 2026 16:23:49 +0000
- NGS Kits Market Forecasts Growth from $6.84 Billion (2025) to $19.36 Billion by 2036, Profiling Illumina, Thermo Fisher Scientific, Roche, Oxford Nanopore & 11 Other Key Players
201-Page Report Finds Library Preparation Leads and Long-Read Sequencing Grows Fastest as Clinical Oncology Testing and Genomics Programs Expand, While Fragmented Reimbursement and Lab Capacity Limits Slow AdoptionDublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "NGS Kits Market: Focus on Workflow, Sequencing Type, Application, End User, and Regional Analysis - Analysis and Forecast Year, 2026-2036" has been added to ResearchAndMarkets.com's offering. The global NGS kits market was valued at $6,843.4 m
Fri, 23 Oct 2026 14:05:00 +0000
- Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More
A wild Thursday saw Treasury yields crater, oil surge past $111, crypto liquidations top $431 million, and Meta's cash flow surprise rattle markets. Now analysts are reshuffling their calls on some of the week's most closely watched names.
Fri, 23 Oct 2026 11:51:51 +0000
- Global Peptide Synthesis Market Forecast to 2031: Size, Share, Trends, and Growth | GLP-1 Boom Lifts Demand for Peptide Synthesis
The global peptide synthesis market is projected to grow from $0.98 billion in 2026 to $1.54 billion by 2031, a new report finds, as GLP-1 drugs and expanding peptide pipelines drive demand for custom synthesis; Thermo Fisher, Merck KGaA, GenScript and Bachem are among 30 companies profiled.Dublin, Oct. 22, 2026 (GLOBE NEWSWIRE) -- "Peptide Synthesis Market: Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. The global peptide synthesis market is projected to grow from
Thu, 22 Oct 2026 13:02:00 +0000
- TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum
Life sciences company Thermo Fisher (NYSE:TMO) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $12.14 billion. Its non-GAAP profit of $6.68 per share was 4.3% above analysts’ consensus estimates.
Thu, 22 Oct 2026 08:38:27 +0000
- Thermo Fisher Scientific (TMO) Stock Faces A Q3 Earnings Disconnect
Thermo Fisher Scientific just reported Q3 2026 numbers that lit up the income statement while the share price barely shrugged. The stock is up about 1% today after the release, a muted move for a business that posted US$12.14b in revenue and adjusted earnings per share of US$6.68 as the headline. The real story is sentiment. Wall Street is rewarding a clean beat and higher full year earnings guidance, but the reaction so far looks more like cautious relief than euphoria. Love that Thermo...
Thu, 22 Oct 2026 06:21:25 +0000
- Medical Giants Thermo Fisher, Danaher Reverse Higher — What Investors Are Seeing
Thermo Fisher and Danaher stocks reversed higher Wednesday after reporting third-quarter metrics and full-year guidance.
Wed, 21 Oct 2026 20:04:11 +0000